ClinicalTrials.gg
RecruitingNCT05786196MAGICUpdated Apr 18, 2025

Multicenter Glaucoma Study Investigating Standalone Canaloplasty

An interventional study of Ab-interno canaloplasty utilizing the iTrack Advance device and Ab-interno canaloplasty utilizing the OMNI Surgical System in Primary Open Angle Glaucoma, sponsored by Nova Eye, Inc.. Recruiting at 5 sites in 3 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Nova Eye, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Glaucoma, Open-Angle with a site in United Kingdom — 5 open to participants now, 7 under way, 1 of them phase 3. Glaucoma, Open-Angle · United Kingdom.

Planned enrollment
19th of 26
86 · median 229
Started
2023
with 2 others
No phase
12 of 34
3 open now
Registered
32nd of 34
by date

Among the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 32nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

5 of the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Glaucoma, Open-Angle with a site in United Kingdom, or all of them as a file.
02

Study summary

A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.

03

Conditions studied

  • Primary Open Angle Glaucoma

Browse trials for

Keywords

  • Canaloplasty
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, 22 years or older at the time of surgery
  • Diagnosed with mild to moderate primary open angle glaucoma
  • Candidate for canaloplasty surgery: i.e., catheterization of Schlemm's canal and subsequent viscodilation of Schlemm's canal, without trabeculotomy
  • Intolerance to medical therapy OR need/willingness to reduce medications
  • At the Screening Visit, IOP of ≤ 30 mmHg while on 1-4 ocular hypotensive medications
  • At the Baseline Visit, unmedicated IOP ≥ 21mmHg and ≤ 36 mmHg, and ≥ 3mmHg higher than medicated IOP
  • Shaffer grade of ≥ 3 in all four quadrants
  • Central corneal thickness ≥ 480µm and ≤ 620 µm
  • Able and willing to comply with the study procedures and attend all follow-up visits
  • Understands and signs the

Exclusion criteria

Exclusion Criteria:

  • Any of the following prior treatments for glaucoma (study eye):

    1. Laser trabeculoplasty

      i. Selective Laser Trabeculoplasty (SLT) conducted within 6-months of the Screening Visit ii. Prior Argon Laser Trabeculoplasty

    2. iStent or iStent Inject within 180 days of the Screening Visit
    3. Endocyclophotocoagulation (ECP) or Micropulse laser
    4. Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma draining device/valve
    5. Prior canaloplasty (ab interno and ab externo)
    6. Prior goniotomy, or trabeculotomy (ab externo and ab interno)
    7. Hydrus microstent
    8. Suprachoroidal stent (e.g., Cypass, iStent Supra, MINIject)
    9. Concurrent IOP-lowering procedure other than use of the iTrack Advance canaloplasty device OR the OMNI Surgical System at the time of surgery (e.g., ECP, CPC, etc.)
  • Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma, pigmentary glaucoma or pseudoexfoliative glaucoma
  • Cataract surgery within 6 months of the Screening Visit in the study eye
  • History of fellow eye with cataract surgery within 30 days of Screening
  • Subjects at significant risk by a of ocular hypotensive medication, and/or subjects where the unmedicated IOP is expected to exceed the upper limit of 36 mmHg
  • Use of systemic medications (either current, within 30 calendar days of Screening exam, or anticipated) that may cause an increase in IOP, (e.g., systemic including inhaled and oral steroids used on a regular basis)
  • Ocular and/or systemic diseases that could affect the corneal endothelium (such as corneal endothelial dystrophy, intraocular inflammation and infection, or congenital abnormalities)
  • History of penetrating keratoplasty or another corneal transplant
  • BCVA of 20/200 or worse in the fellow eye not due to cataract
  • Previous treatment with OMNI or iTrack (Note: permitted if fellow eye only was treated)
  • BCVA of 20/50 or worse in the study eye not due to posterior capsular opacification
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    iTrack Advance

    Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.)

    Device: Ab-interno canaloplasty utilizing the iTrack Advance device

  • Active comparator
    OMNI Surgical System

    Ab-interno canaloplasty utilizing the OMNI Surgical System

    Device: Ab-interno canaloplasty utilizing the OMNI Surgical System

Interventions

  • DeviceAb-interno canaloplasty utilizing the iTrack Advance device

    360 degree microcatheterization and viscodilation of Schlemm's canal

  • DeviceAb-interno canaloplasty utilizing the OMNI Surgical System

    360 degree microcatheterization and viscodilation of Schlemm's canal

06

What researchers measure

Primary outcomes

  1. The mean change in unmedicated Intraocular pressure (IOP) at Month-12 compared to baseline

    IOP will be measured at each visit with Goldmann applanation tonometry

    Time frame: 12 months

  2. Percentage of eyes achieving a 20% or greater reduction in unmedicated Intraocular pressure (IOP) at Month-12 compared to baseline and without any other intervention (medication or secondary surgery)

    IOP will be measured at each visit with Goldmann applanation tonometry

    Time frame: 12 months

07

Study locations

5 of 5 sites recruiting
  • Breyer Kaymak Klabe Augenchirurgie
    Düsseldorf, Germany
    Recruiting
    • Karsten Klabe, MD · Contact
  • Hospital Clinico San Carlos, Servicio de Oftalmologia
    Madrid, Spain
    Recruiting
    • Jose Martinez de la Casa, MD · Contact
  • Princess Alexandra Eye Pavilion, NHS Lothian
    Edinburgh, United Kingdom
    Recruiting
    • Andrew Tatham, MD · Contact
  • St. Paul's Eye Unit, Liverpool University
    Liverpool, United Kingdom
    Recruiting
    • Neeru Vallabh, PhD · Contact
  • Manchester Royal Eye Hospital
    Manchester, United Kingdom
    Recruiting
    • Leon Au, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 43 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Mar 27, 2023
StartActual
May 9, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05786196
Lead sponsor
Nova Eye, Inc.
Collaborators
Nova Eye Medical GmbH
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
May 9, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 18, 2025

Study contacts

Mike Pickrel
Contact
mpickrel@nova-eye.com
1-800-391-2316
Shamil Patel, MD, MBA
principal investigator · Eye Physicians and Surgeons of Arizona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion